SCHEMBL31489409

SCHEMBL31489409

CC[C@H](c1ccc(F)cn1)n1cc(-c2ccc(F)c(-c3ccn4nc(N)nc4c3)n2)cn1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.34
FGFR2 P21802 2/20 0.34
FGFR3 P22607 2/20 0.34
PIK3CG P48736 14/20 0.34
PIK3CD O00329 13/20 0.34
PIK3CA P42336 6/20 0.34
RIPK1 Q13546 1/20 0.31
MAPK1 P28482 1/20 0.31
ROCK2 O75116 1/20 0.31
PAK4 O96013 1/20 0.30
JAK1 P23458 1/20 0.30
PIK3CB P42338 1/20 0.30
CSNK1A1 P48729 1/20 0.30
AAK1 Q2M2I8 1/20 0.30
PIP4K2C Q8TBX8 1/20 0.30
CSNK1G1 Q9HCP0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31489384 1.00 FGFR1 (0.34) FGFR1FGFR2FGFR3PIK3CGPIK3CD
SCHEMBL31489873 0.88 ROCK2 (0.31) FGFR1FGFR2FGFR3PIK3CGPIK3CD
SCHEMBL31489735 0.88 ROCK2 (0.31) FGFR1FGFR2FGFR3PIK3CGPIK3CD
SCHEMBL31489703 0.81 PIK3CG (0.36) FGFR1FGFR2FGFR3PIK3CGPIK3CD
SCHEMBL31489876 0.80 PIK3CG (0.39) PIK3CGPIK3CDPIK3CARIPK1ROCK2
SCHEMBL31489304 0.80 PIK3CG (0.39) PIK3CGPIK3CDPIK3CARIPK1ROCK2
SCHEMBL31489386 0.80 PIK3CG (0.35) FGFR1FGFR2FGFR3PIK3CGPIK3CD
SCHEMBL31489516 0.80 PIK3CG (0.35) FGFR1FGFR2FGFR3PIK3CGPIK3CD
SCHEMBL31489471 0.78 PIK3CG (0.38) FGFR1FGFR2FGFR3PIK3CGPIK3CD
SCHEMBL31489539 0.78 PIK3CG (0.34) PIK3CGPIK3CDPIK3CARIPK1PAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025072395-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-04-03 WO disclosed